Anika Therapeutics | ANIK - Operating Profit


Anika Therapeutics reported $646K in Operating Profit for its fiscal quarter ending in December of 2025.





Operating Profit Change Date
Abbott USD 2.13B 281M Jun/2026
Agenus USD 15.05M 656K Mar/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
Integra LifeSciences USD 41.29M 29.82M Jun/2026
Intrexon USD -60.84M 26.62M Jun/2024
J&J USD 7.48B 860M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
MacroGenics USD -33.44M 21.34M Mar/2026
Merit Medical Systems USD 60.4M 16.25M Jun/2026
Rigel Pharmaceuticals USD 14.06M 13.61M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.38B 449M Jun/2026
Smith & Nephew USD 505M 65M Jun/2026
Stryker USD 1.79B 687M Jun/2026
Veracyte USD 23.96M 4.88M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026
Zimmer Biomet Holdings USD 344.7M 50.4M Jun/2026